Abstract
Genome-wide association studies (GWASs) are typically based on the analysis of single nucleotide polymorphisms (SNPs) and often exclude more complex genetic variants, such as short tandem repeats (STRs). Here, we report the results of GWAS analyses systematically assessing the role of STRs, both imputed and directly genotyped by whole genome sequencing (WGS), on risk for Alzheimer’s disease (AD) in a large collection of ∼330,000 individuals (3,287 AD cases; 47,048 AD-by-proxy cases, 283,111 controls) from the UK biobank. Using imputed (or WGS-derived) STR genotype data, we identified 14 (WGS: one) independent loci showing evidence for genome-wide significant association with AD risk.
While most identified loci had already been highlighted by SNP-based GWAS, we detected new STR-based signals near the genes SNX32 (chr. 11q13) and WBS1 (chr. 17q11). In addition, we delineated several other loci where STRs (and not SNPs) either represent the lead signal (ABCA7) or make substantial contributions to the SNP-driven associations (HLA-DRB1, MINDY/ADAM10, and APOE). Heritability analyses estimated that STRs account for at least 3% of the total phenotypic variance of AD in this dataset. Aligning our top STRs with DNA methylation and transcriptome profiles from human brain samples suggests that several STRs may unfold their effects by impacting gene expression. Future work needs to confirm our results and delineate the likely considerable role that STRs play in the genetic makeup of AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource under Application Number 81874. We acknowledge the Oxford Brain Bank, supported by Brains for Dementia Research (BDR) (Alzheimer Society and This work was funded by the Deutsche Forschungsgemeinschaft ("STaR-AD" project to V.D. [2354/1-1] and L.B. [BE2287/9-1) and the Cure Alzheimer's Fund as part of the Alzheimers Genome ProjectTM (to V.D. and L.B.). C.M.L. was supported by the Heisenberg Program of the DFG (LI 2654/4).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee of the UK Biobank approved collection of the UK Biobank data obtained under application ID 81874.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Access to the UK Biobank resource is available via application (https://www.ukbiobank.ac.uk/). Here all data will be uploaded within 6 months after publication (Application Number 81874) and will be available to any individuals with an approved UKB project. Summary statistics will be made public upon publication and on reasonable request.
